Eisai Announces Plans to Enter Russian Healthcare Market

           Eisai Announces Plans to Enter Russian Healthcare Market

  PR Newswire

  HATFIELD, England, March 26, 2013

HATFIELD, England, March 26, 2013 /PRNewswire/ --

  Company's plans for global business expansion underscores Eisai's  human
                        health care (hhc)   mission

Eisai EMEA (Europe, Middle East and Africa) announces today the expansion of
its operations by establishing a new sales and marketing operation in Russia
based in Moscow. Eisai's market entry will be based on launching its in-house
developed innovative breast cancer treatment, Halaven™ (eribulin). The launch
is expected to be during Q2 2013. Following this, Eisai expects to launch its
epilepsy portfolio including: Zonegran ^® (Zonisamide), Exalief ^®
(eslicarbazepine acetate), and will seek regulatory approval of Fycompa ^®
(perampanel) and Inovelon ^® (rufinamide).

The Russian healthcare market is large and one of the fastest growing in the
world. The pharmaceutical industry has seen significant expansion over the
last few years and it holds strong potential for double-digit growth in the
next six years. ^[1] The value of goods and services on the Russian
pharmaceutical market is expected to reach USD 22.1 billion by 2016. ^[2]
Analysts estimate that, by 2020, the Russian pharmaceutical market is expected
to reach a value of $60 billion, with annual growth rates of at least 15
percent. ^[3]

Commenting on the planned market entry, Gary Hendler, Eisai President & CEO,
Russia and EMEA, said: "Eisai's entry into Russia is fully aligned with the
company's wider strategy of establishing a solid foundation in the EMEA
region. We currently have a number of products in the final stages of approval
and hope to launch four to five products within a year of market entry. This
will allow Russian patients' to have access to innovative treatments not
previously available to them and further supports Eisai's human health care
(hhc) mission to satisfy unmet medical needs and contribute to the health and
well-being of people worldwide."

As part of the company's globalisation strategy set out in its mid-term
strategic plan in 2011 "HAYABUSA",

Eisai seeks to expand its global presence by 2015 in an effort to achieve its
objective of making contributions to more than 500 million patients worldwide.

Notes to Editors

About Eisai's Commitment to Improving Global Access to Medicines

Today, it is estimated that some 2.7 billion* people around the world live on
US$ 2 or less per day. Most of these 2.7 billion people do not have access to
essential health care and treatment despite the availability of effective
medicines. This is an international challenge that needs to be solved through
collaborations among governments, international organisations such as the WHO,
non-governmental organisations and pharmaceutical companies.

In line with its human health care (hhc) mission, Eisai is committed to
improving global access to medicines over the medium-to-long term through
partnership strategies that involve working with governments, international
organisations, private entities and non-profit organisations. Specifically,
the company has developed and is implementing a five-target approach to
improve access to medicines worldwide. The five key components are: product
creations, strategic solutions, capacity building, quality innovation, and
long-term investment.

For further information on Eisai's Access to Medicines initiatives, please
visit the Access to Medicines page on the Eisai Global website:

* Source: World Bank (2005)

About Eisai Eisai is one of the world's leading research and development (R&D)
based pharmaceutical companies and we define our corporate mission as "giving
first thought to patients and their families and to increasing the benefits
health care provides," which we call human health care ( hhc ). Eisai
concentrates its R&D activities in three key areas:

· Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss
· Oncology including: anticancer therapies; tumour regression, tumour
suppression, antibodies, etc · Vascular/Immunological reaction including:
thrombocytopenia, rheumatoid arthritis, psoriasis, and inflammatory bowel

With operations in the U.S., Asia, Europe and its domestic home market of
Japan, Eisai employs more than 11,000 people worldwide. From its Europe based
Knowledge Centre in Hatfield, UK, Eisai has recently expanded business
operations to include the expanded territory of Europe, the Middle East,
Africa and Russia (EMEA). Eisai EMEA undertakes sales and marketing operations
in over 20 markets, including the United Kingdom, France, Germany, Italy,
Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway,
Portugal, Iceland, Czech Republic, Slovakia, the Netherlands, Belgium,
Luxembourg, the Middle East and Russia. For further information please visit:

1. Russian Pharmaceutical Market Summary
(Accessed Jan 2013)

2. Russian Pharmaceutical Market
(Accessed Jan 2013)


Date of preparation: March 2013Job Code: Corporate-UK2011

Contact: Media Enquiries: Eisai Europe Ltd, Charlotte Andrews / Cressida
Robson, +44-(0)7947-231513 / +44-(0) / . Tonic Life Communications, Siobhan Reilly / Moira
Gitsham, +44-(0)207-798-9999 / +44-(0)7788-191434,,
Press spacebar to pause and continue. Press esc to stop.